Src family non-receptor tyrosine kinase, and is tyrosine-phosphorylated by Fyn on Tyr-18. Also, tyrosine-phosphorylated tau is present in the neuropathology of AD. To determine whether alterations in the tau-Fyn interaction might correlate with disease-related factors in AD and FTDP-17, we have performed real-time surface plasmon resonance studies on a panel of 21 tau constructs with Fyn SH3. We report that the interaction between Fyn SH3 and 3R-tau was 20-fold higher than that with 4R-tau. In addition, the affinity between 4R-tau and Fyn SH3 was increased 25-45-fold by phosphorylation-mimicking mutations or by FTDP-17 mutations. In vitro kinase reactions show that tau, with lower affinity SH3 interactions, exhibited a lower level of Tyr-18 phosphorylation under our reaction conditions. Lastly, we have demonstrated that tau is phosphorylated on Tyr-18 in the tau P301L mouse model for tauopathy (JNPL3). In summary, our results suggest that diseaserelated phosphorylation and missense mutations of tau increase association of tau with Fyn. Because these effects are mediated through the 4R component of the tau population, these results also have implications for the FTDP-17 diseases caused by increased expression of 4R-tau. Our data support a role for the Fyn-tau interaction in neurodegeneration.
The ability of microtubule-associated protein tau to interact with microtubules is mediated by its carboxyl-terminal domain, which contains three or four copies of a microtubule-binding motif. In the middle portion of tau is a proline-rich domain that we have previously shown to contain a PXXP motif that interacts with the SH3 domain of Src family non-receptor tyrosine kinases (1) . In human neuroblastoma cells, tau co-immunoprecipitated with the non-receptor tyrosine kinase family member Fyn, and we have recently reported that Fyn phosphorylated tau at its amino terminus (Tyr-18) (2) . Although this phosphorylation does not affect the ability of tau to bind microtubules, this phosphorylated form of tau is present in the neurofibrillary tangles of Alzheimer disease (AD) 2 as well as in preparations of paired helical filaments from AD brain (2) . We hypothesize that the interaction between Fyn and tau may have a role in the signaling events underlying neuropathology. A role for Fyn in AD has been suggested by immunocytochemical studies showing alterations in Fyn staining in AD brain (3, 4) . Moreover, brain slices from Fyn-deficient mice show protection from neurotoxicity induced by A␤ (5) , the other prominent component of AD neuropathology, and Fyn depletion reduces the synaptotoxicity and neurotoxicity exhibited by an A␤-based mouse model for AD (6) . Also, Fyn can activate GSK3␤ (7) and cdk5 (8) , kinases known to phosphorylate tau at disease-associated sites. These findings suggest Fyn as a link between amyloid and tau pathology.
Tau pathology is also found in frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17), a group of age-related neurodegenerative diseases caused by autosomal dominant mutations in the tau gene (reviewed in Refs. 9 and 10). The mutations, of which over 30 have been identified, can be divided into splice site and missense mutations (reviewed in Refs. 11 and 12) . The splice site mutations predominantly result in the overexpression of mRNA encoding tau with four microtubule-binding repeats (4R-tau) relative to those with three repeats (3R-tau). As in AD, the tau lesions in FTDP-17 diseases comprise accumulations of abnormally phosphorylated tau, and many of the phosphorylated serine and threonine tau epitopes in AD have also been found in In this study, we have investigated the impact of FTDP-17 mutations on the Fyn-tau interaction. Using the surface plasmon resonance (SPR) biosensor technique, we determined the kinetic parameters of the Fyn SH3-tau interaction for two alternatively spliced isoforms of tau (3R-tau and 4R-tau) and the effect of FTDP-17 and phosphorylation-mimicking mutations. Our results identify several functional differences between these proteins that were not present when similar assays were conducted with Src SH3. The significance of our SH3 interaction results were then tested by in vitro kinase assays; these assays indicated that the tyrosine phosphorylation of tau at Tyr-18 correlated with the SH3 domain interaction. Lastly, we determined that a mouse model of an FTDP-17 disease contained tyrosine-phosphorylated tau. Overall, our data provided evidence for the importance of the Fyn-tau interaction in the neurodegenerative process and led us to present a new hypothesis regarding the role of 4R-tau in disease.
EXPERIMENTAL PROCEDURES
Expression of Recombinant Tau-Human tau with 3-or 4-microtubule-binding repeats (352-or 383-residue isoforms) were subcloned into either pET-3d or pET-17b vectors (Novagen, Madison, WI) for bacterial protein expression using standard techniques. The following mutations were introduced using site-directed mutagenesis (QuikChange mutagenesis kit, Stratagene, La Jolla, CA) ( Fig. 1 ): 1) FTDP-17 missense mutations V337M, G272V, R406W, P301L, and R5H; and 2) phosphorylation-mimicking mutations S199D, S199D/ S202D, S396D, S404D, S396D/S404D, and T231D/S235D. A construct with an internal deletion of the PXXP motif (⌬P) has been previously described (1) . All constructs were verified by DNA sequencing. tau proteins were expressed in Escherichia coli and purified as previously described (13) . The purity and size of wild type and mutant tau proteins were analyzed by gel electrophoresis and MALDI-TOF, showing homogeneous preparations of the expected molecular weights (supplemental Figs. S1 and S2). Prior to SPR analysis, protein was desalted, degassed, and equilibrated in HBS-EP buffer (10 mM Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20). Protein concentrations were determined by Bradford assay. Each protein was freshly diluted to obtain different concentrations using HBS-EP buffer containing 1 mM dithiothreitol prior to SPR analysis. GST-Fyn SH3 and GST-Src SH3 fusion proteins were affinity-purified on glutathione-Sepharose beads as described by the manufacturer (Amersham Biosciences). For SPR, GST-Fyn SH3 and GST-Src SH3 were used at 10 g/ml in HBS-EP buffer containing 1 mM dithiothreitol.
Surface Plasmon Resonance-SPR experiments were performed at 25°C using the BIAcore 3000 (BIAcore Inc., Piscataway, NJ). Goat anti-GST antibody was immobilized on two flow cells (FC1 and FC2) of a CM4 sensor chip by amine coupling at pH 5.0 in 10 mM sodium acetate, according to BIAcore instructions. Approximately 6200 resonance units corresponding to 6.2 ng/mm 2 goat anti-GST antibody was immobilized on each surface. A blank surface (FC3) was made by ethanolamine deactivation of the activated dextran surface.
For SPR, GST fusion proteins were diluted to 10 g/ml in HBS-EP buffer and injected into FC2. This resulted in 150 -200 resonance units on the surface matrix, corresponding to 150 -200pg/mm 2 of GST fusion protein bound to the GST antibody in FC2. Next, purified tau protein was injected on all three flow cells (FC1, -2, and -3) at a flow rate of 40 l/min and resonance units measured. After each binding cycle, the surfaces were regenerated with 10 mM glycine (pH 2.2) to remove the GST fusion protein ϩ Tau complex from the antibody surface. The first flow cell (FC1) was the minus GST protein control channel and was subtracted from the sample channel (FC2) during the run. Bulk refractive index contributions were therefore expected to be 0 or not significant in reference-subtracted sensorgrams. To obtain the association constant (on-rate or k a ) and the dissociation constant (off-rate or k d ), the interaction between GST fusion protein and different tau constructs was measured at tau concentrations of 1250, 1000, 750, 500, and 250 nM. To correct for nonspecific binding, blank runs were performed with HBS-EP buffer on all three surfaces before and after each binding analysis; this value was subtracted prior to kinetic analysis. The resulting sensorgrams were analyzed using the 1:1 Langmuir binding model in the BIAevaluation version 3.1 software program (BIAcore Inc.). Quality of the kinetic fit was determined by the residuals and the 2 values (supplemental Fig. S3 Immunocytochemistry-For immunocytochemistry, paraffin-embedded brain sections (4 m thick) were prepared from 8-month-old P301L tau-transgenic mice as previously described (14) . Sections were sequentially immunostained, first with TG3 (1:10, generously provided by Dr. Peter Davis (15)) or AT8 (1:200, Pierce) followed by 9G3-biotin. Rhodamine-conjugated anti-mouse IgM or IgG secondary antibodies were used for TG3 or AT8 detection. Alexa-488-conjugated streptavidin (1:200, Molecular Probes, Eugene, OR) was used for 9G3 detection. Sections were visualized using the Nikon E800 microscope. 9G3-biotin was prepared using the EZ-Link NHS-PEO solid phase biotinylation kit (Pierce).
RESULTS

3R-tau Binds to Fyn SH3 with a Higher Affinity than 4R-tau-To
investigate the interaction between Fyn and tau, we used SPR spectroscopy to quantitate the interaction between tau and the SH3 domain of Fyn. We started by comparing two wild type tau proteins that are generated by alternative splicing. Adult human brain expresses both 3R-tau and 4R-tau, whereas fetal human expresses only 3R-tau. In this study, we have used the shortest 3R-tau and 4R-tau isoforms. Neither contain inserts at the amino terminus and differ only in the number of microtubule-binding repeats.
The real-time interaction between 3R-tau and GST-Fyn SH3 was measured at 25°C by sequentially injecting proteins onto sensor chip surfaces with immobilized goat anti-GST antibody. SPR responses of injected tau were recorded with and without a prior injection of GSTFyn SH3. Prior to kinetic analysis, the tau-alone control response was subtracted from the tau-plus GST-Fyn SH3 response. Our data indicated that 3R-tau interacted with GST-Fyn SH3 with an equilibrium dissociation constant (K D ) of 0.32 M (TABLE ONE, representative SPR sensorgram shown in Fig. 2 ). This value was the average of five K D values calculated from the measured kinetic rates of association (k a ) and dissociation (k d ) measured at five tau concentrations (average k a and k d values are shown in supplemental Tables S1 and S2). It should be noted that the value of K D is inversely proportional to the affinity between interacting proteins and that, therefore, a lower K D indicates a higher affinity between two interacting partners.
Our previous data obtained by GST "pull-down" assay identified a 233 PXXP motif in tau that interacted with the SH3 domain of Fyn (1) . SPR analysis confirmed that the 3R-tau mutant lacking the 233 PXXP motif (⌬P) interacted very poorly with GST-Fyn SH3. The interaction displayed 12-fold lower affinity (K D ϭ 4 M) compared with that of 3R-tau (TABLE ONE) . In addition, we measured the interaction between Fyn SH3 and a tau mutant, where both Thr-231 and Ser-235 had been replaced with aspartic acid, thus mimicking phosphorylation at the PXXP motif. Thr-231 in tau is phosphorylated by several kinases, including GSK3␤ and cdk5, and the presence of phospho-Thr-231, as well as phospho-Ser-235, in AD have been shown by phospho-specific antibody probes and mass spectrometry data (reviewed Refs. 16 -18) . The interaction between Fyn SH3 and the 3R-tau-T231D/S235D mutant showed an 8-fold reduction in affinity (K D ϭ 2.8 M; TABLE ONE). These results confirm the importance of the PXXP motif in mediating the tau-Fyn SH3 interaction.
Surprisingly, although 4R-tau interacted with GST-Fyn SH3, the affinity (K D ϭ 6.77 M) was 20-fold lower compared with 3R-tau (TABLE ONE, representative SPR sensorgram shown in Fig. 2 ). To confirm these results, we tested 4R-tau prepared from two different prokaryotic plasmids, each plasmid sequence having been confirmed by DNA sequencing and protein analyzed by MALDI-TOF. Our data indicated that the alternative splicing of tau dramatically alters the interaction of tau with Fyn. Previously, we had shown that tau also interacted with the SH3 domain of Src. Therefore, as a comparison, we also analyzed the interaction between tau and Src SH3. For 3R-tau, the interaction with Src SH3 resembled that with Fyn SH3, showing a comparable K D value of 0.17 M (TABLE TWO) . However, for 4R-tau, the interaction with the Src SH3 showed a much lower K D than for Fyn SH3 (K D ϭ 0.26 M for Src versus K D ϭ 6.77 M for Fyn), suggesting that for 4R-tau, binding to Src was preferred relative to Fyn. As measured by K D , there was no significant difference between the interaction of 3R-tau or 4R-tau with Src SH3. Therefore, the observed difference between 3R-tau and 4R-tau was specific for the tau-Fyn interaction.
Amino Acid Replacements Far from the PXXP Impact on SH3 Interactions-As our data suggested that phospho-Thr-231 and phospho-Ser-235 would interfere with the association of tau with SH3, we tested two other disease-related phosphorylation sites (Fig. 1) . Mass spectrometry, as well as immunocytochemical data, have also established phospho-Ser-199/202 and phospho-Ser-396/404 as abnormally phosphorylated tau sites in disease. To study the effects of phosphorylation at these sites, which are recognized by monoclonal antibodies AT8 and PHF1, respectively, we synthesized tau constructs that mimicked phosphorylation by converting Ser-199, -202, -396, and -404, either individually or in pairs, to aspartic acid. When 3R-tau was mutated to mimic phosphorylation at the AT8 site, either as a single S202D or double S199D/S202D replacement, the protein showed a significant reduction in affinity (95 and 76-fold, respectively) to the Fyn SH3 (TABLE ONE) . Interestingly, an opposite effect was observed when 4R-tau carrying these same mutations were tested. 4R-S202D and 4R-S199D/S202D displayed a 26-and 42-fold increase, respectively, in affinity.
Mutations in 3R-tau that mimic phosphorylation at the PHF1 site, either as a single S396D or double S396D/S404D mutant, resulted in modest differences in binding that were not statistically significant. In contrast, similar mutations introduced in 4R-tau (4R-S404D and 4R-S396D/S404D) displayed 45-and 42-fold increases in affinity, respectively (TABLE ONE) . Therefore, although 3R-tau phosphorylation-mimicking mutants have either decreased or unchanged binding affinities to Fyn SH3, similar 4R mutants have enhanced binding affinities.
To assess whether FTDP-17 missense mutations affect the tau-Fyn interaction, we first investigated four mutations (V337M, G272V, R406W, and R5H) in 3R-tau (Fig. 1) . In comparing the binding kinetics of the mutants to GST-Fyn SH3, all four mutants tested showed modest 2-3-fold increases in binding affinity that were not statistically significant. In contrast, when we investigated the same four mutants and P301L in 4R-tau, all mutants showed a significant increase in binding affinity to Fyn SH3. The affinities for the interactions with the V337M, G272V, R406W, and R5H mutants were all at least 30-fold higher than wild type 4R-tau, with the P301L mutant showing the highest increase (42-fold) (TABLE ONE) . Lastly, FTDP-17 mutations, either in 3R or (Table S1 ). 4R-tau, did not significantly alter their binding to Src SH3 (TABLE  TWO) . In summary, the SPR data has indicated that pseudophosphorylation and FTDP-17 mutations differentially affect 3R-and 4R-tau with regards to their interaction with the Fyn SH3 domain. Our results are summarized in Fig. 3 , where we have graphed the reciprocal of the K D (1/K D ) as an indication of binding affinity, because the K D value reflects the rate of the dissociation of the interaction. For the graph, 1/K D was normalized to the 3R-tau-Fyn SH3 value, which was set at 100. In addition, we used the calculated mean of the K D values gathered for each group of similar modifications, because the differences between the values within each group were not statistically significant. We noted that 4R-tau binds Fyn SH3 less well than 3R-tau and that pseudophosphorylation at AT8 or PHF1 or FTDP-17 mutation increases the affinity of 4R-tau to match that of unmodified 3R-tau (Fig. 3, left) . In contrast, 3R-tau was affected only by pseudophosphorylation at AT8, which resulted in a decrease in affinity. The differences noted between the splicing isoforms and for the FTDP-17 mutations were not found for the Src SH3 interaction (Fig. 3, right) . 233 
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PXXP Motif in Tau Is Essential for Tyr-18 Phosphorylation by Fyn or Src Kinase-A functional consequence of SH3 domain interactions
for Fyn or Src might be to direct substrates to the catalytic domain of the kinase (19) . Using co-transfected COS cells, we have recently determined that Tyr-18 in human tau was phosphorylated by Fyn and Src (2) . If the interaction between tau and the SH3 domain of Fyn or Src was critical for the phosphorylation of Tyr-18 of tau, in vitro phosphorylation of Tyr-18 might be expected to be consistent with the SPR results. Therefore, to extend our understanding of the functional significance of the tau-SH3 domain interaction, we performed in vitro kinase reactions with wild type tau and tau mutants using Fyn or Src kinases and a phospho-Tyr-18-specific antibody (anti-PY18) to detect the tyrosine phosphorylation of tau (2) .
When the 3R-tau ⌬P mutant was used as a substrate for Fyn, there was a decrease in PY18 (Fig. 4, lane 2) . To quantitate the level of phosphorylation, we measured the ratio of PY18 to total tau. This parameter indicated that ⌬P was phosphorylated 15-fold less than wild type tau (Fig. 4) . Similarly, the T231D/S235D mutant was phosphorylated 12-fold less than wild type tau (Fig. 4, lane 3) . Assays performed with Src on the ⌬P and T231D/S235D proteins similarly showed 19-and 4-fold less PY18, respectively (Fig. 4, lanes 5 and 6) . The correlation between these results and the SPR data suggest that the in vitro phosphorylation of tau at Tyr-18 by Fyn or Src kinase is strongly dependent on the interaction between the PXXP motif and the SH3 domain.
Because 3R-⌬P and 3R-T231D/S235D proteins showed a positive correlation between SH3 binding and Tyr-18 phosphorylation, one might anticipate that the 4R-tau and FTDP-17 mutants would exhibit similar results. However, when kinase reactions were carried out with these proteins under the same conditions as above (reaction incubation time of 6 h), we found minimal differences between 3R-tau, 4R-tau, and FTDP-17 mutants (data not shown). We then considered the fact that, although the ⌬P and T231D/S235D proteins had alterations that directly impacted on the site of interaction between Fyn and tau, the inclusion of exon 10 in 4R-tau and the FTDP-17 mutations represented changes that were all located some distance away from the PXXP motif (Fig. 1) . In addition, because SPR data is derived from real-time binding measurements, the 6-h incubation condition might not reflect kinetic effects exerted by indirect conformational alterations. Moreover, we had noted that all of the changes in K D had resulted from changes in the measured rate of association (k a ). Thus, we performed a time course of phosphorylation to determine whether the inclusion of exon 10 or the FTDP-17 mutations might affect the phosphorylation of Tyr-18 primarily during the initial stages of the reaction. By terminating the Fyn kinase reaction after 0.5, 1, 2, 5, 10, 20, 60, and 240 min of incubation, we found that the levels of phosphorylation, as determined by the ratio of PY18 to total tau, were higher for 3R-tau than 4R-tau (Fig. 5A) . The measured differences were statistically significant, as determined by unpaired t test. In addition, although phosphorylation of the 3R-V337M mutant was similar to 3R-tau (Fig. 5B) , the 4R-R406W and P301L mutants had significantly higher levels of phosphorylation when compared with 4R-tau (Fig. 5C ). These findings support our SPR results.
Tyr-18 Phosphorylated Tau in P301L Tau Transgenic Mouse BrainGiven that FTDP-17 mutations affected the tyrosine phosphorylation of tau and our previous finding that Tyr-18 of tau was phosphorylated in AD, we tested an FTDP-17 mouse model (14) for Tyr-18 phosphorylation of tau. Brain sections from an 8-month-old P301L tau transgenic mouse were probed with an antibody specific for phosphorylated Tyr-18 (9G3), whereas AT8 or TG3 were each used as a control antibody to identify tau pathology. We found 9G3 Table S3 . ** indicates that the differences between the K D value for 4R-tau and those of 3R-tau and all 4R-tau mutants tested were statistically significant (p Ͻ 0.001). * indicates that the difference between the K D value for the 3R-tau AT8-mimicking mutants and 3R-tau was statistically significant (p Ͻ 0.001). Note that pseudophosphorylation and FTDP-17 mutations differentially affect the affinity of 3R-tau and 4R-tau for Fyn SH3. 1 and 4) , 3R-⌬P (lanes 2 and 5) , and 3R-T231D/S235D (lanes 3 and 6) were incubated with Fyn (left) or Src (right) for 6 h (see "Experimental Procedures"). Reactions were probed for phospho-Tyr-18, total tau, and Fyn or Src. Phospho-Tyr-18 and total tau were quantitated by phosphorimaging. Graph shows the ratio of PY18 to total tau. Values are represented as mean Ϯ S.E. from three experiments.
labeling in the brain stem, basal ganglia, entorhinal cortex, and hippocampus, coinciding with AT8-positive neurons (Fig. 6) ; TG3 also labeled the same neuronsas9G3.Atthesubcellularlevel,wenotedthattheTG3stainingpatternwas often punctate (Fig. 6, insets) , as reported for the pre-tangle stage in AD brain (20) . Interestingly, the 9G3 staining pattern in the same neuron appeared subtly different from the TG3 or AT8 patterns. These results suggest that tau pathology in the P301L mouse model has differentially phosphorylated tau species.
DISCUSSION
Our earlier results demonstrated that Tyr-18 of tau was tyrosinephosphorylated early in development and that this phosphorylated form of tau also existed in the neurofibrillary tangles of AD (2) . Because tyrosine phosphorylation of tau by Fyn on Tyr-18 could be the consequence of the interaction between tau and the SH3 domain of Fyn, we have extended our investigation of this interaction using a panel of 21 wild type and mutated tau proteins, surface plasmon resonance technology, and in vitro kinase reactions. From our data, the overall conclusions were: 1) the inclusion of the exon 10 sequence in 4R-tau profoundly influences the binding of the SH3 domain of Fyn but not of Src, 2) amino acid changes removed from the tau PXXP-binding motif that either mimic phosphorylation or cause frontotemporal dementia increase the Fyn SH3 binding with 4R-tau, and 3) the Fyn SH3 interaction is critical to tyrosine phosphorylation at Tyr-18.
The equilibrium dissociation constant measured by SPR for the interaction between tau and the SH3 domain of Fyn was consistent with those that have been measured for other SH3 domain interactions in signal transduction (reviewed in Refs. 21 and 22) . Based on three-dimensional structural data obtained for liganded SH3 domains, the interacting PXXP motif on tau would be classified as a class I ligand for the SH3 domain (reviewed in Refs. 21 and 23). Such ligands adopt a polyproline II left-handed helix conformation that makes contact with the relatively flat hydrophobic surface of the SH3 domain (reviewed in Ref. 22) . Class I ligands typically contain a basic amino acid (Arg-230 in tau) located upstream of the PXXP core that aids in the interaction with the "specificity" pocket of the SH3 domain. In addition, phosphoserine or acidic residues adjacent to the core motif disrupt the association (24) . Therefore, it was not surprising that the replacements of Thr-231 and Ser-235 with aspartic acid in tau decreased its association with Fyn SH3. This result replicated our previous data using phosphorylated tau peptides (25) and confirmed the ability of aspartic acid to mimic Ser/Thr phosphorylation.
As the 233 PXXP motif is conserved in all tau isoforms, it was surprising that 4R-tau, which contains exon 10-encoding amino acids 275-305, had decreased association with the SH3 domain of Fyn. This suggested that the exon 10 sequence impacted on a region 40 amino acids upstream. A widely held notion is that tau exists as an extended protein without significant secondary or tertiary structure and that it adopts structure upon interacting with other proteins, such as microtubules. If true, then our data would suggest that, although 3R-tau could be induced to fold in a particular manner upon interacting with the SH3 domain, 4R-tau was inhibited from adopting a similarly folded structure, presumably by the presence of exon 10. Interestingly, based on microtubule-binding studies, Feinstein and co-workers (26) have previously proposed that an intramolecular interaction existed between the proline-rich region and the microtubule-binding domain. In particular, their data led them to propose a model whereby the sequence 224 KKVAVVR 230 , which is adjacent to the PXXP, would affect the function of the inter-repeat area 274 KVQIINKK 281 (Fig. 1) . Moreover, this inter-repeat sequence is present only in 4R-tau, and therefore, the proposed intramolecular interaction would only take place in 4R-tau. Because the PXXP lies in the 44-amino-acid region between the interacting areas, such an intramolecular interaction could either decrease the accessibility of the PXXP to SH3 binding or prevent the PXXP from adopting the conformation of a polyproline II left-handed helix. Furthermore, our results suggest that the intramolecular interaction could take place in the absence of microtubules under reducing conditions and that this conformation would not be altered by the presence of the , and 240 min as described under "Experimental Procedures." Ratio of PY18 to total tau was calculated following phosphorimaging analysis. A, 3R-tau had a higher level of phosphorylation than 4R-tau. By unpaired t test, the difference between the levels was significant (p Յ 0.05). B, the V337M mutation in 3R-tau did not result in significantly higher levels of Tyr-18 phosphorylation, by unpaired t test. C, R406W and P301L mutations in 4R-tau increased levels of Tyr-18 phosphorylation. The difference between 4R-tau and 4R-R406W was significant (p Յ 0.05) as well as that between 4R-tau and 4R-P301L (p Յ 0.01).
SH3 domain-binding surface. This argues that tau has some secondary structure.
Other investigators have also proposed various intramolecular interactions between tau domains. The tau repeat domain mediates both microtubule binding and filament formation, and regions outside of the repeat domain have been reported to influence both functions. For instance, regions flanking the repeat region enhance the microtubule interactions of the repeat region (13, 27) , and the amino and carboxyl termini of tau influence its ability to form filaments (28 -30) . A "propolymerization" conformation has been proposed for tau, wherein the amino terminus folds backwards to interact with the microtubule-binding region (28) . In this conformation, the PXXP would be located within the looping portion of tau. Depending on the microtubule-binding region involved, the loop may be different for 3R-versus 4R-tau. Recently, in microtubule polymerization studies, functional differences between these tau isoforms have been reported, suggesting that mechanistically, 4R-tau may act qualitatively differently relative to 3R-tau with regards to microtubule dynamics (31, 32) . These differences could be caused by isoform-specific folding.
Isoform-specific effects were also observed when we investigated the effects of amino acid replacements on the ability of tau to bind to the Fyn SH3 (summarized in Fig. 3 ). As replacements in areas removed from the PXXP affected 3R-tau differently from 4R-tau, these data support the notion that the Fyn SH3 interaction is capable of revealing conformational differences between the two isoforms. Another observation supporting conformational differences between 3R-and 4R-tau was their differential binding to Fyn versus Src SH3. In the absence of structural data on tau, it is unclear how phosphorylation at the AT8 or PHF1 site might alter the PXXP region in an isoform-specific manner. Pseudophosphorylation at the AT8 site affected microtubule association (33) . Similarly, tau filament formation was enhanced by pseudophosphorylation at the PHF1 site (30) . FTDP-17 mutations have also been reported to affect microtubule association and filament formation (reviewed in Refs. 9, 34, and 35). These studies support the idea that amino acid replacements or modifications in tau can exert effects over a distance and suggest the presence of structure in tau. Our results suggest that, when 4R-tau is hyperphosphorylated at AT8 or PHF1 sites or mutated at FTDP-17 sites, conformational changes result that enhance Fyn SH3 binding to the PXXP motif.
In determining the relevance of our SPR results toward tau function as a substrate for tyrosine phosphorylation, we found that the relative differences could be revealed in kinase reactions that were monitored before equilibrium conditions were reached. This is not unlike what has been reported for differences between FTDP-17-mutated taus in microtubule assembly and filament formation assays (36 -39) . The in vivo relevance of our non-equilibrium conditions is supported by the fact that tyrosine phosphorylation is a dynamic event wherein phosphorylation events usually occur within an hour of cell activation. For instance, tyrosine phosphorylation of tau and paxillin in response to A␤ are upand down-regulated within 10 min of A␤ addition (40) . Therefore, the increased levels of Tyr-18 phosphorylation seen in the 4R-FTDP-17 mutant (Fig. 5 ) is likely to have relevance in vivo. The presence of tau phosphorylated on Tyr-18 in the transgenic tau P301L mouse model supports the hypothesis that the Fyn-tau interaction has a role in neurodegenerative disease.
Based on our SPR data, disease-related phosphorylation or FTDP-17 mutation preferentially increased the affinity of 4R-tau for Fyn, resulting in a gain of function for tau. During neuropathogenesis, phosphorylation occurs at many sites, and although it is known that in vitro the phosphorylation of 4R-tau differs from 3R-tau (41-43), the extent to which these differences occur in neuronal cells is unknown. Also, FTDP-17 mutations may affect phosphorylation (reviewed in Refs. 17 and 18).
We speculate that, in AD, disease-related phosphorylation would increase the association of Fyn with 4R-tau. Furthermore, in frontotemporal dementias, the overall ability of the tau population to associate with Fyn would also be increased, either through increased representation of phosphorylated 4R-tau or through the presence of 4R mutant proteins. These increased Fyn-tau interactions would then promote neurodegeneration. Our speculations suggest a unified model capable of explaining the autosomal dominant aspect of the FTDP-17 diseases, the relationship between the splicing and missense mutations, and the significance of tau phosphorylation in AD and in FTDP-17. This working model warrants continued investigation of the Fyn-tau interaction and the role of this interaction as a molecular switch in activating downstream signaling events that may lead neurons toward neurodegeneration.
